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T cells have been established as core effectors for cancer therapy; this has moved the
focus of therapeutic endeavors to effectively enhance or restore T cell tumoricidal activity
rather than directly target cancer cells. Both antibodies targeting the checkpoint inhibitory
molecules programmed death receptor 1 (PD1), PD-ligand 1 (PD-L1) and cytotoxic
lymphocyte activated antigen 4 (CTLA4), as well as bispecific antibodies targeting CD3
and CD19 are now part of the standard of care. In particular, antibodies to checkpoint
molecules have gained broad approval in a number of solid tumor indications, such as
melanoma or non-small cell lung cancer based on their unparalleled efficacy. In contrast,
the efficacy of bispecific antibody-derivatives is much more limited and evidence is
emerging that their activity is regulated through diverse checkpoint molecules. In either
case, both types of compounds have their limitations and most patients will not benefit
from them in the long run. A major aspect under investigation is the lack of baseline
antigen-specific T cells in certain patient groups, which is thought to render responses
to checkpoint inhibition less likely. On the other hand, bispecific antibodies are also
restricted by induced T cell anergy. Based on these considerations, combination of
bispecific antibody mediated on-target T cell activation and reversal of anergy bears
high promise. Here, we will review current evidence for such combinatorial approaches,
as well as ongoing clinical investigations in this area. We will also discuss potential
evidence-driven future avenues for testing.
Keywords: anti-CTLA4, anti-PD1, bispecific T cell activating antibodies, immune checkpoint blockade,
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INTRODUCTION
Since its inception in the 1940s, drug-based cancer therapy has been centered on targeting the
cancer cell through different strategies aiming at reducing their growth (1). With the development
of recombinant techniques and the hybridoma technology (2) for the generation of monoclonal
antibodies, therapies utilizing the immune system have entered the clinical realm from the 1990s
(3, 4). However, the main target of antibodies remained the cancer cell or cancer cell associated
processes such as growth factors (5). The clinical value of these advances is unchallenged and has
enhanced patients’ prognosis in a number of indications.
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More recently, a paradigm change has occurred in clinical
oncology, establishing the immune system in general and T
cells in particular as therapeutic effectors. Antibodies targeting
and activating T cells have been approved for the treatment of
advanced cancer types such as metastatic melanoma, advanced
non-small cell lung cancer or renal cell carcinoma (6, 7).
This advance has been made possible through the recognition
that cancer cells suppress the immune system, and especially
adaptive anti-tumoral immunity to progress to overt clinical
disease (8). In this process, suppression of T cell function
and recognition of cancer antigens through induction of T
cell anergy or dysfunction has been identified as an essential
step. Based on these seminal discoveries, antibodies neutralizing
the anergy mediating or T cell suppressing molecules PD1,
PD-L1 or CTLA4 have entered clinical practice (6, 7). These
antibodies have led to unparalleled response rates and even
cures in previously untreatable medical conditions, including
advanced metastatic melanoma (9). As especially the PD1-
PD-L1 axis appears to be a central process across cancer
entities, it is not surprising that the antibodies nivolumab,
pembrolizumab (both anti-PD1) or atezolizumab, avelumab and
durvalumab (anti-PD-L1) are approved for a growing number
of indications based on efficacy (10). Due to their mode
of action, these drugs are now being used in combination
trials both with conventional treatments such as chemo- or
radiotherapy, as well as other immunotherapeutic strategies
in over 1,000 open clinical trials (10). A major limitation of
checkpoint blockade is the specificity of the approach, as any
T cell encountering its antigen outside of the tumor tissue
may be unleashed. While this is highly desirable in terms of
breadth of the anti-tumoral immune response, a significant
issue are autoimmune side effects which can be life threatening
(9).
Another, potentially more selective, approach to redirect T
cells against cancer cells are bispecific antibodies (BiAb) (11).
BiAb can bind two antigens simultaneously and can act as a
bridging agent for two different cell types. One of the most
widely used concepts are T cell-activating bispecific antibodies
(TABs), which would activate T cells in the vicinity of cancer cells
targeted through simultaneous binding of a tumor associated
antigen (TAA) (12). For the purpose of this review we will use
the short form TAB for any bispecific molecule activating T
cells, irrespective of the format or the target molecule. A TAB
targeting CD19 and CD3 (blinatumomab) effectively redirects T
cells against acute lymphocytic leukemia (ALL) cells and induced
remission in refractory patients (13). This has led to its approval
for the treatment of certain ALL types. Many other TABs are
under investigation for several indications (11). However, even
in the context of ALL, their activity appears to be limited and
additional strategies are required to enable their use in a broader
clinical setting (14). In the present review, we will give an
overview of current developments in the TAB field, identify
resistance and escape mechanisms that need to be overcome
to enable TAB activity and summarize data on most advanced
combination strategies utilizing TAB together with checkpoint
blockade.
T CELL ENGAGING BISPECIFIC
ANTIBODIES FOR CANCER THERAPY
In the 1960s, the first reports on bispecific antibody derivatives
were on antigen-binding fragments (Fabs) from two different
polyclonal sera re-associated into bispecific F(ab’)2 molecules
(15). The development of the hybridoma technology in 1975
allowed researchers to produce large amounts of monoclonal and
later bispecific antibodies (2, 16, 17). The advent of engineered
bispecific antibody formats set the stage for applications beyond
simple antigen neutralizing, antagonistic or agonistic binding.
Over three decades of research have come up with more
than 100 molecular formats (18). At least a quarter of those
formats have also been used to design TABs (19). For space
reasons only approved formats and designs currently being
clinically tested in combination with checkpoint blockade are
described in this review (Figure 1). A comprehensive overview
of all other formats can be found in Wu and Cheung
(19).
In most formats in clinical development, a monovalent binder
for CD3 is combined with a monovalent TAA binding site (a
1:1 valency). Apart from valency, the TAB’s affinity for CD3
is designed so that it does not trigger T-cell receptor signaling
through CD3, unless it is presented to the T cell in a multivalent
fashion bound to a TAA on a target cell [Figure 1A, (12)]. In
any case, T cells are redirected to a TAA regardless of their
initial specificity, can exert direct cytoxicity and induce cytokine
responses triggering further bystander activation.
The first clinically approved TAB was Catumaxomab
(Removab, a bispecific IgG antibody) in 2009, targeting CD3 and
epithelial cell adhesion molecule (EPCAM) for the treatment
of malignant ascites. Catumaxomab is a trifunctional antibody,
consisting of mouse IgG2a (EPCAM) and rat IgG2b (CD3)
(Figure 1B) (i) and is produced using quadroma technology
(20). While Catumaxomab was voluntarily withdrawn from
the market in 2013, two more TABs based on the same format,
targeting CD20 or Her2 have been tested in early phase clinical
trials (21, 22).
A very small format to generate 1:1 valency are bispecific T cell
engagers (BiTEs). BiTEs are also known as tandem single chain
variable fragments (scFvs) and are composed of two scFvs, each
with a unique antigen specificity (Figure 1B) (ii). The entire BiTE
molecule consists of one continuous polypeptide of ∼55 kDa,
compared to 150 kDa for a conventional IgG antibody (23). As
with full IgG format TABs, one scFv in BiTEs targets the CD3
and the other scFv targets a TAA.
Blinatumomab (Blincyto, Amgen) became the first and so far
only clinically approved BiTE for the treatment of ALL. It engages
T cells through CD3 binding, while the other scFv is specific
for CD19, expressed by B cells, including B-lineage leukemias
and lymphomas (24, 25). In a phase II trial, Blinatumomab
achieved complete remissions in 69% of patients with relapsed
or refractory ALL (26).
Even smaller than BiTEs, dual-affinity retargeting (DART)
proteins have a diabody format where one VL chain is
followed by the VH chain of the second binder and the
Frontiers in Oncology | www.frontiersin.org 2 July 2018 | Volume 8 | Article 285
Kobold et al. Bispecific T Cell Activators + Checkpoint Blockade
FIGURE 1 | (A) Therapeutic concept utilized by TABs: Binding of tumor associated antigen (TAA) on cancer cell leads to crosslinking of CD3 on T cells, activation
irrespective of TCR specificity and tumor cell lysis. (B) Molecular formats of TABs which are approved or currently tested in combination with checkpoint blockade. (i)
Bispecific rat/mouse chimeric, quadroma derived antibodies with 1:1 valency, e.g., Catumaxomab. (ii) BiTE: two single chain variable fragments (scFv) connected via
flexible linkers as a continous polypeptide with 1:1 valency, e.g., Blinatumomab. (iii) DART-Fc: two VL chains that each have their corresponding VH chains
interchanged and are expressed as two separate chains. One of the chains has a knob-Fc domain, a third chain entails the whole-Fc domain, 1:1 valency, such as
MGD007. (iv) CrossMAB-Fab: heterodimeric constant light chain assembly combined with knobs-into-holes mutations for heterodimeric heavy chain pairing with 1:2
valency, e.g., CEA-TCB. (v) Bispecific fully human IgG format (hIgG) with a common light chain and heterodimeric heavy chains with 1:1 valency, e.g., REGN1979.
two polypeptide chains align in a head-to-tail fashion. DARTs
also face the problem of low in vivo half-life, which can
be partially solved by fusion of an Fc domain (DART-Fc,
Figure 1B) (iii) (27).
While the above formats all use symmetric design to create
1:1 valencies for CD3 and TAA targeting, evidence suggests
that 1:2 design with two binding sites for the TAA and one
for CD3 might be beneficial to generate strong binding to
tumor cells while avoiding CD3 activation in the absence of
TAA. A versatile format termed CrossMab technology enables
the heterodimeric constant light chain assembly and together
with the knobs-into-holes method to generate heterodimeric
heavy chain antibodies, which allows not only the generation of
bispecific antibodies in full IgG format, but also 1:2 valencies
(Figure 1B) (iv) (28). This method was used to develop a TAB,
which binds CD3 and carcino-embryonic antigen (CEA), with
a 1:2 valency [Figure 1B, (29)]. Most TABs use fully human
BiAb formats with near-native antibody architecture (Figure 1B)
(v). Currently, 10 different IgG format TABs are being clinically
tested (19).
LIMITATIONS AND RESISTANCE
MECHANISMS TO TABs
To date catumaxomab and blinatumomab are the only TABs
that have achieved regulatory approval. Due to the premature
withdrawal of the former, our knowledge of the TAB limitations
comes primarily from traditional monoclonal antibodies and
blinatumomab (13).
Moving from hematological malignancies onto solid tumors, a
major limitation of all antibodies is their (in-)ability to reach their
target. While sites such as lymph nodes and the bone marrow
have excellent accessibility, it is lower for other tissues such as
synovial joints and the kidney. For the central nervous system
(CNS), antibody drug exposure can be <1% relative to systemic
circulation. Poorly organized vasculature also limits blood flow
rates and contributes to inefficient drug delivery in solid tumors
(11, 30). To date, no clinical successes using TABs in solid tumors
have been reported. Dose-limiting toxicity and low half-life can
be prohibitive for the use of BiTEs in such tumors. Sufficient
dosing to reach poorly perfused tumors without causing serious
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adverse events (AEs) is challenging. Another problem with non-
lymphoid tumors is that TAAs are often not exclusively expressed
on transformed cells, raising the issue of on-target but off-tumor
toxicities which can be dose and efficacy limiting.
A crucial issue with the polyclonal activation of T cells by
TABs, independent of TAA binding, is a potentially fatal cytokine
release syndrome (CRS) similar to the adverse events observed
with a CD28 superagonist antibody (14, 31). The CRS goes hand
in hand with disease load in patients and correlates with dosage,
in turn limiting application either to lower dosage or to patients
with lower tumor burden.
TAB therapies also run into the issue of tumor mutations
and subsequent treatment escape. For blinatumomab, about
15% of patients experience CD19-negative relapses of ALL
due to a disrupted CD19 membrane export (32). In such
patients, blinatumomab selects for CD19-negative ALL cells and
prevents further BiTE activity. A notion that might counteract
this limitation is epitope spreading occurring under active
immunotherapy. Evidence for epitope spreading comes from
preclinical studies with catumaxomab and a BiTE targeting an
intracellular oncoprotein (33, 34). However, the setting where
blinatumomab is applied might not be beneficial for epitope
spreading as these patients frequently have pancytopenia either
as consequence of disease or treatment and might not be able to
mount an effective T cell response.
Two major reported ALL escape mechanisms during
treatment with blinatumomab included increased frequencies
of regulatory T cells (Tregs) (35) and increased levels of PD-
L1 expression on B-precursor ALL cells (36). Tregs suppress
effector T cell activation through CTLA4 and other mechanisms
[reviewed in (37)]. However, even when T cells get fully
activated, upregulation of PD1 will lead to inhibitory signaling
after binding to PD-L1 expressed by the tumor cells. These
mechanisms induce effector T cell suppression and exhaustion
or dysfunction, which can be therapeutically countered with
checkpoint blockade (Figure 2A).
COMBINATION OF TABs WITH
CHECKPOINT BLOCKADE
The blockade of the PD1—PD-L1 axis restores blinatumomab
activity in vitro (38). Comparable data has been described
with the anti-CD3 × anti-CD33 BiTE AMG330 (39). AMG330
upregulated PD1 on T cells and PD-L1 on AML blasts in
vitro. Lytic potential, T cell activation and proliferation are
strongly enhanced upon blockade of the PD1-PD-L1 axis (39,
40). Addition of costimulatory agonistic anti-CD28 antibodies
to AMG330/T cell/blast coculture boosted blast lysis (40).
In line with these results, using a novel anti-CD3 × anti-
CD307 bispecific antibody, suppression of T cell mediated
killing was observed on myeloma cells through PD-L1 and
selective antibody-mediated blockade restored T cell activity
(41). Finally, the use of a bispecific single chain antibody
converting negative PD-L1 signaling into positive costimulation
through CD28 on T cells has been shown to improve the
activity of blinatumomab in vitro (42). These cancer entities
and molecule spanning synergies underpin the relevance of the
combination of PD1-PD-L1 disruption and bispecific T cell
activating antibodies in hematologic malignancies. They have
prompted the design and the initiation of ongoing clinical studies
combining blinatumomab with checkpoint inhibition (Table 1).
In other non-hematological entities, various TAB are under
testing and development and it is not surprising that a potential
synergistic activity with checkpoint inhibition is also being
evaluated. As seen in hematological malignancies, both PD1 on T
cells and PD-L1 on tumor cells are upregulated upon treatment
with TABs (29, 43). However, the value of blockade of PD1—
PD-L1 interaction is more controversial in such indications and
might depend on the molecule used, as well as the tumor site.
Activity of anti-CD3 × anti-CEACAM5 × anti-Trop2 antibody
was enhanced when combined with PD1-blockade in vivo (44).
PD1-PD-L1 inhibition also enhanced lysis mediated by anti-
CD3 × anti-CEA bispecific T cell engager but was unable to
restore T cell activity completely upon induced T cell exhaustion
(45). These later results point toward additional mechanisms
impairing T cell activity under these conditions. Along these
lines, exhausted T cells have also been described to have reached
a state where such combination alone can no longer convert
them into an active T cell (46). In such a situation, a TAB
may even have detrimental activity in conjunction with other
treatment modalites and worsen activation induced cell death
in combination with radiation. Combination of an anti-CD3 ×
anti-CD133 bispecific antibody with radiation accelerated tumor
growth due to cell death, which could only be partially prevented
by PD1 blockade (47). Another important aspect seems to be the
exact antibody format or targeting moiety used, as some TABs
targeting HER2 on breast cancer cells are found to be insensitive
to PD1-PD-L1 mediated T cell suppression toward their activity,
while blockade of the axis might enhance the lytic potential of
another anti-HER2 TAB (48, 49).
While so far a major focus of research has been on the PD1-
PD-L1 axis based on the mode of action which is predicted to be
at the tumor site, the use of the other approved checkpoint axis
blocker against CTLA4 (ipilimumab) has also been investigated.
CTLA4 blockade ameliorates the activity of TABs, although to a
more modest extent than seen with PD1 or PD-L1 blockade (33).
Some studies, also indicate that blockade of both axes is required
to achieve superior tumor cell killing (46).
Preliminary clinical results have been reported for the
combination of atezolizumab (anti-PD-L1) with anti-CD3 ×
anti-CEA TCB and for an anti-PD1 antibody together with anti-
CD3 × anti-CD20 bispecific antibodies in colorectal carcinoma
and B cell lymphoma respectively (50, 51). Both studies have
disclosed signs of activity and responses, indicating that the
combination will also be valuable clinically. Longer follow up and
full disclosure of the results will be required to assess the clinical
value of the strategy.
A major mechanistical aspect from such a combination
strategy, which can prevent resistance and escape is the induction
of epitope spreading. Tumor reduction by TABs will make
tumor antigens accessible to the immune system and enable
induction of specific T cells which can be unleashed or further
boosted by checkpoint blockade (Figure 2B). Vice versa, a similar
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FIGURE 2 | Strategies to overcome tumor escape mechanisms through combining TABs with checkpoint blockade. (A) Activated T cells upregulate checkpoint
molecules such as PD1 and CTLA4, which can lead to their suppression and anergy, allowing tumors to escape. Combination therapy of TABs with checkpoint
blockers unleashes suppressed T cells and restores tumor cell killing via TAB. This in turn releases new tumor antigens. (B) Tumor antigens are taken up by antigen
presenting cells (APCs) and prime new T cell clones, this broadens the antigen specific T cell response and leads to tumor eradication through antigen spreading even
if the tumor downregulates TAB specific TAA.
TABLE 1 | Clinical trials testing TAB in combination with checkpoint blocking antibodies Tested compounds, molecular targets, format, indication and trial status are
indicated.
Compounds Target Format of TDB Indication Identifier Status
Blinatumomab and Pembrolizumab CD19 and PD1 BiTE Refractory or relapsed diffuse
large B cell lymphoma
NCT03340766 Not yet recruiting
Blinatumomab, Nivolumab,
Ipilimumab
CD19, PD1,
CTLA4
BiTE Refractory acute lymphoblastic
leukemia
NCT02879695 Recruiting
Anti-CEA x anti-CD3 bispecific
antibody and atezolizumab
CEA and PD-L1 CrossMAB-Fab Advanced CEA+ solid tumors NCT02650713 Recruiting
Anti-PD1 and anti-CD3 x anti-CD20
antibodies
CD20 and PD1 cLC-hetero-H-
chain IgG
B lymphoid malignancies NCT02651662 Recruiting
Anti-PD1 and anti-CD3 x anti-gpA33 gpA33 and PD1 DART-Fc Refractory or metastastic
colorectal cancer
NCT03531632 Recruiting
A comprehensive overview of clinical trials using TAB alone or in combination with other than checkpoint inhibition is found elsewhere (19).
mechanism is envisionable when tumor reduction is propelled
by checkpoint blockade and immune response is boosted by
the TAB. Preclinical examples of epitope spreading have been
reported for BiTE and checkpoint blockade (34, 52, 53), paving
the way for the concept that epitope spreading might be most
prominent when both modalities are combined (Figure 2). On
the other hand, checkpoint blockade targeting for example
CTLA4 has been reported to be most effective when preexisting
immunity against TAA was detected at baseline (54). A notion
that is countered by others, as similarly, de novo induction of
anti-tumor responses have been described to be the best predictor
of clinical activity (55). Along the same lines, both de novo
and preexisting immunity is associated with treatment response
to PD1-blockade (56). Existing evidence thus points toward
epitope spreading as an important determinator of response
to immune checkpoint blockade. Clinically, mutational load
is a predictive marker for response to checkpoint blockade.
Similar thoughts would thus conceptualize the notion that more
mutations provide more targets for T cells and thereby a better
epitope spreading (57). As both checkpoint blockade and TAB are
associated with the occurrence of epitope spreading to varying
degrees, we argue that combinations will enhance the likelihood
of this important mode of activation to happen. It would also
come with the advantage of prolonged activity over time even
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when the drugs are discontinued and to potentially reduce the
occurrence of antigen-loss variants. Evidence for the benefit of
this strategy and for its mode of action will come from future and
ongoing clinical trials.
RISKS ASSOCIATED WITH THE
COMBINATION OF TAB AND CHECKPOINT
BLOCKADE
Most of our knowledge on the side effects to be expected by
the clinical use of TABs comes from the use of blinatumomab.
The side effects are considerable with over 80% of patients
experiencing side effects of grade three or above (side effect
requiring hospitalization and/or life threatening) (58). Apart
from neutropenia, infections and other common side effects
in hemato-oncology, blinatumomab is also associated with
severe CRS and neurological symptoms of unknown ethiology.
In specialized centers these are in general manageable and
eventually completely resolve inmost patients. In contrast, severe
side effects of grade three or above are typically less frequent
when targeting the CTLA4 or PD1 pathway with checkpoint
blockade (∼28 and 21%, respectively) (59). The safety profile
is, however, very distinct with mainly autoimmune related
side effects including colitis and polyendocrinopathies. These
autoimmune phenomena can be managed if recognized and
treated adequately but might also lead to the need of life long
hormone substitutions in a number of cases when endocrine
organs are affected. Limited data exists for the potential safety
profile of the combination of TAB with checkpoint blockade in
clinical trials. The combination of the CEA TCB with anti-PD-
L1 blockade suggest that toxicities of either agent do not multiply
and the most frequent adverse events so far were infusion related
reactions and diarrhea (60). However, this data need to be
interpreted with caution, as so far only published as a conference
abstract and experience with combined checkpoint blockade
suggests that toxicities from immune active agents might at least
add up to each other for a more detrimental safety profile. A
longer follow up and results from ongoing prospective trials are
expected to answer these questions.
CONCLUSION AND OUTLOOK
T cell activating bispecific antibodies have considerable activity
in refractory B-ALL but only a fraction of the treated patients
will benefit from it in the long run. A major mechanism
limiting the activity of bispecific antibodies in ALL and other
indications appears to be T cell anergy and exhaustion driven
by, among others, the PD1-PD-L1 axis. Preclinical evidence
suggests that bispecific antibody activity under these settings can
be restored or even enabled when combined with antibodies
to checkpoint molecules. Under this combination, induction
of epitope spreading may be an important mode of action
of a combinatorial treatment. However, current evidence also
indicates that not all bispecific antibodies, nor all indications
will benefit from such combinations forcing the need for
more detailed research. Although outside of the scope of
the present review, it is important to note that bispecific T
cell engaging antibodies might also act in synergy with other
immunotherapeutic modalities such as agonistic stimulatory
antibodies (CD137, OX40 or others). Using a similar approach
as in TABs, negative checkpoint signals could be converted into
immune activating signals, e.g., anti-CD47 × anti-CD19 (61),
enabling phagocytosis and subsequent antigen presentation to T
cells. Along the same lines, other bispecific antibody types such as
the anti-angiopoetin-2× anti-VEGF bispecific antibody RG7221,
which can increase immune cell infiltration through vasculature
normalization, might synergize with checkpoint blockade. An
ongoing clinical study is currently investigating this question
(NCT01688206), but no results on the combined activity have
been reported yet (62). Current and upcoming clinical trials will
provide data to expand the clinical value of such combination
strategies and plans for further investigation and application.
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